[Use of cortisone in the symptomatic treatment of malignant bronchopulmonary tumors].
86% of 1703 subjects with primary malignant bronchopulmonary tumours treated over a period of 5 years responded solely to symptomatic management. Attention is drawn to the poor results offered by polychemotherapy and to satisfactory treatment of 82 patients with 6-methylprednisolone acetate. This drug was chosen on account of its ease of administration and fewer side-effects by comparison with cortisones given per os.
D001984:Bronchial Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005334:Fever / Q000188:drug therapy; D006801:Humans; D007273:Injections, Intramuscular; D008175:Lung Neoplasms / Q000188:drug therapy*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use
D008775:Methylprednisolone
Considerazioni sull'impiego dei cortisonici nel trattamento sintomatico dei tumori broncopolmonari maligni